CN112770739B - (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸及相关化合物在治疗发育障碍中的用途 - Google Patents

(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸及相关化合物在治疗发育障碍中的用途 Download PDF

Info

Publication number
CN112770739B
CN112770739B CN201980052607.5A CN201980052607A CN112770739B CN 112770739 B CN112770739 B CN 112770739B CN 201980052607 A CN201980052607 A CN 201980052607A CN 112770739 B CN112770739 B CN 112770739B
Authority
CN
China
Prior art keywords
day
syndrome
pharmaceutically acceptable
acceptable salt
difluoromethylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980052607.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN112770739A (zh
Inventor
马修·杜林
布雷特·亚伯拉罕斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CN112770739A publication Critical patent/CN112770739A/zh
Application granted granted Critical
Publication of CN112770739B publication Critical patent/CN112770739B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201980052607.5A 2018-06-07 2019-06-07 (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸及相关化合物在治疗发育障碍中的用途 Active CN112770739B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862681913P 2018-06-07 2018-06-07
US62/681,913 2018-06-07
PCT/US2019/035934 WO2019236938A1 (en) 2018-06-07 2019-06-07 Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

Publications (2)

Publication Number Publication Date
CN112770739A CN112770739A (zh) 2021-05-07
CN112770739B true CN112770739B (zh) 2023-12-12

Family

ID=68765508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980052607.5A Active CN112770739B (zh) 2018-06-07 2019-06-07 (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸及相关化合物在治疗发育障碍中的用途

Country Status (12)

Country Link
US (3) US10813899B2 (https=)
EP (1) EP3813816B1 (https=)
JP (1) JP7387179B2 (https=)
KR (1) KR102744830B1 (https=)
CN (1) CN112770739B (https=)
AU (1) AU2019280980B2 (https=)
CA (1) CA3102786A1 (https=)
ES (1) ES2948263T3 (https=)
IL (2) IL279220B2 (https=)
MX (2) MX2020013290A (https=)
PL (1) PL3813816T3 (https=)
WO (1) WO2019236938A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279220B2 (en) 2018-06-07 2023-12-01 Ovid Therapeutics Inc Use of (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid and related compounds, (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and vigabatrin In the treatment of developmental disorders
GB2591389A (en) 2018-08-18 2021-07-28 Ftf Pharma Private Ltd Pharmaceuticals solution for oral dosage
WO2024058812A1 (en) 2022-09-16 2024-03-21 Pyros Pharmaceuticals, Inc. Vigabatrin liquid pharmaceutical composition
AU2024220546A1 (en) * 2023-02-17 2025-09-04 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid for gastrointestinal tract disorders and as an immunomodulatory agent
CN120641091A (zh) * 2023-02-17 2025-09-12 奥维德医疗公司 (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗糖尿病和前驱糖尿病中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105517546A (zh) * 2013-09-09 2016-04-20 阿尔考布拉有限公司 治疗脆性x综合征及相关疾病的方法
WO2017062942A2 (en) * 2015-10-09 2017-04-13 Northwestern University (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
WO2005120496A2 (en) 2004-05-24 2005-12-22 Regents Of The University Of California TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE
WO2009033818A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2790820A1 (en) 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
WO2012042314A1 (en) 2010-10-02 2012-04-05 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US20140315992A1 (en) 2011-07-07 2014-10-23 The Children's Hospital Of Philadelphia Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism
EP2806867A4 (en) 2012-01-27 2015-09-02 Catalyst Pharmaceutical Partners Inc METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS
US20150224164A1 (en) 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
CA2966642C (en) 2014-11-07 2023-03-28 Northwestern University Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma
US20170348232A1 (en) * 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
US10632088B2 (en) 2016-10-10 2020-04-28 Northwestern University Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria
EP4692048A3 (en) * 2017-02-08 2026-04-01 Ovid Therapeutics Inc. Methods of treating cdkl5 disorders with the compound ov329
AU2018370164B2 (en) * 2017-11-14 2024-08-15 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for reducing or treating developmental disorders including fragile X syndrome, Angelman syndrome or Rett syndrome
KR20250051780A (ko) 2018-05-25 2025-04-17 노오쓰웨스턴 유니버시티 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산의합성을 위한 공정
IL279220B2 (en) 2018-06-07 2023-12-01 Ovid Therapeutics Inc Use of (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid and related compounds, (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and vigabatrin In the treatment of developmental disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105517546A (zh) * 2013-09-09 2016-04-20 阿尔考布拉有限公司 治疗脆性x综合征及相关疾病的方法
WO2017062942A2 (en) * 2015-10-09 2017-04-13 Northwestern University (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Design and Mechanism of (S)‑3-Amino-4- (difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid, a Highly Potent γ‑Aminobutyric Acid Aminotransferase Inactivator for the Treatment of Addiction;Jose I. Juncosa等;《Journal of the American Chemical Society》;第140卷(第6期);2151-2164 *

Also Published As

Publication number Publication date
IL304270A (en) 2023-09-01
CA3102786A1 (en) 2019-12-12
IL304270B1 (en) 2024-06-01
MX2020013290A (es) 2021-04-29
AU2019280980A1 (en) 2021-01-07
KR102744830B1 (ko) 2024-12-19
EP3813816B1 (en) 2023-06-07
US11660277B2 (en) 2023-05-30
KR20210035802A (ko) 2021-04-01
AU2019280980B2 (en) 2025-02-27
IL279220B2 (en) 2023-12-01
IL279220A (en) 2021-01-31
PL3813816T3 (pl) 2023-07-31
ES2948263T3 (es) 2023-09-07
US12285397B2 (en) 2025-04-29
IL279220B1 (en) 2023-08-01
WO2019236938A1 (en) 2019-12-12
US20230255914A1 (en) 2023-08-17
EP3813816C0 (en) 2023-06-07
US20210100763A1 (en) 2021-04-08
US10813899B2 (en) 2020-10-27
JP7387179B2 (ja) 2023-11-28
CN112770739A (zh) 2021-05-07
MX2023006497A (es) 2023-06-21
US20190374492A1 (en) 2019-12-12
EP3813816A4 (en) 2021-06-23
JP2021527053A (ja) 2021-10-11
IL304270B2 (en) 2024-10-01
EP3813816A1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
CN112770739B (zh) (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸及相关化合物在治疗发育障碍中的用途
CN110461319A (zh) 治疗癫痫发作紊乱和prader-willi综合征的方法
US20100063116A1 (en) Use of pramipexole or a salt thereof for the treatment of parkinson's disease
CN109715144A (zh) 使用双胍类治疗发育障碍的方法
US10653652B2 (en) Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction
US20190328719A1 (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine
WO2020018779A1 (en) Use of phenylethylidenehydrazine to treat seizure disorders, developmental disorders, neurological disorders, behavioral disorders and addiction
CN112930182A (zh) 加波沙朵用于治疗图雷特综合征、抽搐和口吃的用途
HK40050398A (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
HK40050398B (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
US11771671B2 (en) Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
HK40016106A (en) Methods of treating seizure disorders and prader-willi syndrome
HK40012437A (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant